Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.
Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. N Engl J Med. 2018;379(19):1846-1850..
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. 2016.
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-153.
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in The Modern Years. Biol Blood Marrow Transplant. 2015.
Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biol Blood Marrow Transplant. 2014.
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.